ENLV Stock Overview
Operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Enlivex Therapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.24 |
| 52 Week High | US$4.59 |
| 52 Week Low | US$0.81 |
| Beta | 1.01 |
| 1 Month Change | -4.62% |
| 3 Month Change | -22.01% |
| 1 Year Change | -66.12% |
| 3 Year Change | -79.26% |
| 5 Year Change | -85.26% |
| Change since IPO | -87.96% |
Recent News & Updates
Recent updates
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
Sep 13
We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully
Apr 04Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Dec 13Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
Jul 25Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?
Apr 05Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Nov 16Enlivex Therapeutics: A Very Enticing Early-Stage Biotech
Sep 30Enlivex to gets US patent covering use of cell therapy Allocetra
Sep 06Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells
Aug 29Envilex Therapeutics reports Q2 results
Aug 22We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Jul 08Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment
Jul 06We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Mar 23Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Nov 25We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Aug 12Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy
Jun 15Enlivex issued new Canadian patent for Allocetra immunotherapy
Jun 01We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn
Apr 29Enlivex shares rise 20% on positive Allocetra data in COVID-19
Feb 03Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Jan 11
Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?
Nov 19Shareholder Returns
| ENLV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.8% | -2.3% | -2.6% |
| 1Y | -66.1% | -6.3% | 24.5% |
Return vs Industry: ENLV underperformed the US Biotechs industry which returned -6.3% over the past year.
Return vs Market: ENLV underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| ENLV volatility | |
|---|---|
| ENLV Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ENLV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ENLV's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Oren Hershkovitz | www.enlivex.com |
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.
Enlivex Therapeutics Ltd. Fundamentals Summary
| ENLV fundamental statistics | |
|---|---|
| Market cap | US$25.73m |
| Earnings (TTM) | -US$18.93m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs ENLV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENLV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.93m |
| Earnings | -US$18.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.86 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ENLV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 01:25 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Enlivex Therapeutics Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |